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SurfactantCentral to gene therapy technology has been the use of cationic polymers as vectors for DNA and RNA
(polyfectins). These have been presumed to be safer than viral systems which, for example, have been found
to switch on oncogenes. Two key polycations that have been intensively researched for use as synthetic
vectors are poly(ethylenimine) and poly(L-lysine). A frequent stumbling block with these polyfectins is that
long-term gene expression in cell lines has not been achieved. Recently it has transpired that both of these
polycations can induce mitochondrially mediated apoptosis. It is the aim of this review to discuss the
mechanisms behind the observed polycation toxicity including roles for little studied cellular organelles in
the process such as the lysosome and endoplasmic reticulum.+44 1273 679333.
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Gene therapy has offered a potential panacea to many heritable
genetic conditions and as such has generated intense research interest
over more than a decade [1–9]. Key to the success of this technology is
high gene transfection rates coupled with low toxicity. Viral vectors
have been the vehicles of choice, with some notable success, such as in
the treatment of patients with severe combined immunodeﬁciency
(SCID) X1 disease [10,11] who were adenosine deaminase deﬁcient.
Advancement in the ﬁeld has been seriously hampered by induction
of severe toxicity and in some cases fatality [11–13]. In order to
counteract the deleterious effects incumbent to current viral based
vectors, a wide range of synthetic vectors have been developed [14–
19]. These have included the polyfectins (cationic polymer–DNA
complex), which are based on cationic macromolecules that condense
DNA or RNA into stable nanostructures for gene delivery. Two of the
most intensely studied polycations are poly(ethylenimine) (PEI) and
poly(L-lysine) (PLL). Branched PEI 25 kDa is perhaps among the most
efﬁcient synthetic transfectants in experimental gene therapy. PEI
condenses DNA into torroidal and globular nanostructures, these can
undergo cellular internalization by endocytic and phagocytic routes[20]. Although a range of mechanisms have been suggested, it is
generally thought that once internalized into the cell, the polycationic
vehicles destabilize endosomal membranes or act as proton sponges
resulting in buffering the low endosomal pH and subsequent
membrane rupture [21–23], which releases the PEI–DNA complexes
into the cytoplasm. Following internalization, poly(L-lysine)s also
localize in early vesicles. However, the PLL–DNA complexes do not
efﬁciently escape from endosomes, but curiously gene expression still
occurs. A consistent problem in the use of these polyfectin
technologies has been a lack of sustained gene expression [24].
Mechanistic studies have shown that both of these polycations
condensed with DNA can induce apoptosis through mitochondrially
mediated pathways as evidenced by release of cytochrome c (Cyt-c)
and subsequent induction of executioner caspases (cysteinyl aspar-
tate-speciﬁc proteases) (Fig. 1) [25,26]. It is the purpose of this review
to discuss these underlying mechanisms of mitochondrially mediated
apoptosis induced by the polycations by PEI and PLL and to explore
possible roles for organelles such as the lysosome and endoplasmic
reticulum [27], that following interaction with polycations can trigger
cell suicide [28] via the mitochondrion.
2. PEI-mediated phase 1 cytotoxicity
An in depth study [25] into the cytotoxicity of PEI employed three
clinically relevant cell lines (lymphoid, endothelia and hepatic) to
Fig. 1. Schematic diagram showing possible polycation-mediated cell damage/death processes and pathways.
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macromolecular analogues on them. The branched PEI was tested in
both free (10 and 30 μg/mL) and complexed with DNA (regardless of
PEI:DNA) and was found to generate signiﬁcant release of lactate
dehydrogenase (LDH) within the ﬁrst hour; this continued in a time-
dependent manner. Concomitantly rapid redistribution (30 min) of
phosphotidylserine (PS) from the inner plasmamembrane to the outer
cell surface was observed. The PS externalization was found to be rapid
at concentrations of 20 μg/mL and above, in contrast at lower PEI
concentrations (10 μg/mL) signiﬁcant translocation was observed after
24 hours.AlthoughPS translocation is ahallmarkof apoptosis [29], it can
also occur during early necrotic-like cell damage. Thus, the initial
conclusion was that binding of PEI molecules to the plasma membrane
proteoglycans [30] results in membrane destabilization and rapid PS
exposure. The time-dependent increase in PS translocation supported
the activation of apoptotic pathway(s). The mechanics of the apoptotic
process result in activated caspases which induce PS “scrambling”
followed by a loss ofmembrane integrity [29,31]. It is difﬁcult to forman
exact opinionon the role of theDNA–PEI complex in this interactiondue
to the fact that the DNA–PEI complex preparations similar to those used
in this study may contain as much as 85% free PEI molecules [23] and
that even by repeated ultraﬁltration procedures not more than 30% of
the free PEI cannot be removed. Although, paradoxically this decreases
the degree of transcription, presumably through a decrease in available
free PEI for membrane rupture [32]. A role for the DNA–PEI complex
alone on membrane destabilization and PS exposure cannot be
ruled out, as in DNA exchange for anionic proteins in the cytoskeleton,
e.g., F-actin [33]. Importantly dissociation in the presence of negatively
charged macromolecules (e.g., heparin) has been observed with PEI–
DNA complexes [23,34].The abovementioned observations were consistent with the
timeline of interaction observed in a previous study involving
intracellular tracking of ﬂuorescently labelled branched PEI–DNA
complexes [21]. Fluorescent clumps were seen to attach at discreet
features of the plasmamembrane in human endothelial-like cells after
30 min incubation. These increased in number over the following 1–
2 hours. By 3 hours post-incubation, ﬂuorescence was generated in
the cytoplasmic vesicles (endosomes and endolysosomes), which
were consistent with complex uptake. Experiments utilizing doubly
labelled PEI–DNA demonstrated disruption of some of the endosomes
initiating at 4 hours post-incubation with evidence of PEI–DNA
separation in the cytoplasm. Nuclear localization (PEI or PEI–DNA)
was frequently observed by 3.5–4 hours after administration to the
cells. The earliest localization of the complexes within the nuclei
preceded the earliest observed transgene expression at 1 hour.
3. PEI-mediated phase 2 cytotoxicity: the role of mitochondria
Signiﬁcant activation of the effector caspase-3 occurred at around
24 hours post-PEI treatment in all three cell lines, and this was
coupledwith loss of plasmamembrane integrity resulting in apoptotic
body formation. Thus, apoptosis represents phase II cytotoxicity.
Inclusion of the caspase-3 inhibitor Ac-DEVD-CHO resulted in
inhibition of apoptosis. The signiﬁcance of the degree of apoptosis
was highlighted by comparison of that produced by PEI to the
established proapoptotic compound doxorubicin hydrochloride
(50 μg/mL ﬁnal concentration). It was found in the case of the Jurkat
T-cells that over 90% were in an apoptotic state following 24 hours
challenge with doxorubicin. The results of caspase-3 activation with
PEI at 10 and 20 μg/mL were approximately 20% and 45%,
1205A.C. Hunter, S.M. Moghimi / Biochimica et Biophysica Acta 1797 (2010) 1203–1209respectively, of the level encountered following treatment with
doxorubicin. Remarkably, an increase in PEI concentration to 50 μg/
mL resulted in twice the caspase-3 activity compared to doxorubicin
at 24 h post-incubation.
The central mechanistic role for the mitochondrion in PEI-induced
apoptosis was initially identiﬁed by determination of a link between
caspase-3 activity and mitochondrial membrane potential (MMP) in
the presence of PEI. A wide range of studies have demonstrated that
MMP loss follows release of Cyt-c [29,35,36]. In order to determine if
MMPwas lost through challenge by PEI and PEI–DNA complexes, a JC-
1 ﬂuorescent cationic dye was used (Fig. 2a). This probe does not
respond to alteration in the plasma membrane potential [37]. Within
intact mitochondria, the JC-1 probe form aggregates that are ﬂuoresce
orange, and following membrane disruption, these are released into
the cytoplasm as monomers that are ﬂuoresce green. The MMP was
found to alter in a time-dependent manner in the Jurkat T-cells and
was consistent with caspases-3 activation at 24 hours.
The effect of both branched and linear PEI on the isolated
mitochondria revealed release of Cyt-c from the intermembrane
space in a time-dependent manner. The Bcl-2-sensitive Cyt-c was
released at concentrations as low as 0.1 µg/mL (Fig. 2b). Remarkably,
no changes were observed in mitochondrial volume, respiration orFig. 2. PEI-mediated alteredmitochondrial functions. Time-dependent changes inmitochond
concentration=30 µg/mL (in free form) and PEI–DNA, weight ratio 3:1. The effect of PEI on
(b). The x and y-axis represent recorded events (arbitrary units). Modiﬁed with permissiondepolarization (Fig. 2b). This indicated that mitochondrial perme-
ability transition was not involved [36,38]. In order to achieve this
result, it would indicate that PEI inserts into and forms a channel in
the outer membrane of the mitochondrion. This channel would have
to be large enough to facilitate Cyt-c release in a similar manner to
that of BAXBH3 peptides or oligomeric Bax [36,39]. Following access
to the intermembrane space executioner caspases may enter and
cleave the 75-kDa subunit of the respiratory complex [40] resulting in
disruption of complex 1 activity, loss of MMP and production of
reactive oxygen species. This results in a drop in ATP levels with loss of
plasma membrane integrity.
The observed phase 1 and phase 2 cytotoxicities were also found
with linear and high molecular weight PEI (750 kDa). Time-
dependent changes in PS expression and caspases 3 activity also
occurred following treatment of Jurkat T-cells at concentrations of 20
and 50 µg/mL. Linear PEI at 10 µg/mL induced signiﬁcant alteration in
MMP, which occurred at 24 hours post-treatment.
4. Poly(L-lysine)s and mitochondrially mediated apoptosis
A wide range of synthetic polyamines including linear and
dendritic poly(L-lysine)s (PLL) have been used for DNA compactionrial membrane potential (a), which was examined by speciﬁc ﬂuorescent probe JC-1. PEI
Cyt-c release from isolated rat liver mitochondria and on other mitochondrial functions
[25].
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cellular internalization, PLL–DNA complexes localize in early endocy-
tic vesicles. Remarkably, in the absence of an endosomotropic agent,
such as chloroquinine or the inﬂuenza virus hemaggluten HA-2
fusogenic peptides [43–49], the PLL–DNA complexes do not efﬁciently
escape from the endosomes but gene expression still occurred [49].
This may indicate an interaction by the PLL with other organelles at a
later stage in its trafﬁcking (late endosome/lysosome), where release
of DNA may be achieved.
PLLs have been associated with cytotoxicity [44,45,50,51], an in
depth investigation into the behaviour of low and high molecular
weight PLLs frequently used in transfection protocols, revealed a
similar pattern of programmed cell death to PEI, mediated through
themitochondrion, with early plasmamembrane damage followed by
late phase (∼24 hours) apoptosis in the human cell lines tested [Jurkat
T-cells, umbilical vein endothelial cells (HUVECs), THLE-3 hepatocyte-
like cell line] [26]. However, both lowmolecular weight poly(L-lysine)
(L-PLL) and high molecular weight poly(L-lysine) (H-PLL) in free form
and complexed with DNA trigger stress-induced apoptosis by
mitochondrial permeabilization. As with PEI, the higher molecular
weight H-PLL (20 µg/mL) brought about a more rapid onset of PS
translocation (30 min–1 hour) in contrast to the L-PLL (20 µg/mL) in
which PS exposure was observed 5 hours post-incubation. Similar
results were obtained with the THLE-3 hepatocytes and HUVECs. The
time delay between PS exposure and executioner caspase-3 activation
was signiﬁcant, with the observed activity of this protease being
signiﬁcantly triggered after 24 hours of treatment with all PLLs
including those complexed to DNA. As with PEI, the caspase-3 activity
was inhibited by Ac-DEVD-CHO. H-PLL was found to be more efﬁcient
than L-PLL in inducing caspase-3 activation. With both PLL molecular
weight sizes at the comparatively lower concentration of 10 µg/mL
caspase activation was also detected. HUVECs were least susceptible
to L-PLL/L-PLL–DNA complexes compared to the other cell lines
indicating variation between cell lines sensitivity and susceptibility to
these polycations. Consistent with previously reported polycation-
induced cellular cytotoxicity [44,45,50,51], both PLLs and PLL–DNA
complexes induced rapid LDH release from all of the cell lines tested
as well as signiﬁcant accumulation of Cyt-c in Jurkat T-cell cytoplasm.
Application of a cell permeable Bax channel blocker [52] reduced Cyt-
c release by approximately 50% but did not affect Cyt-c release from
the mitochondria by L-PLL, indicating different modes of mitochond-
rially mediated apoptosis by the two polymers (Fig. 3a). As a control
experiment (Bcl-2 inhibition) [53] was found to accelerate acceler-
ated cell death in all cases (Fig. 3a). Increased levels of cytoplasmic
Cyt-c resulted in immediate detection of caspase-9 activation and
signiﬁcant caspase-3 activity, fully supporting the mitochondrially
mediated pathway to apoptosis. Remarkably, with isolated mitochon-
dria, H-PLL but not L-PLL was able to release Cyt-c (Fig. 3b).
Furthermore, in contrast to PEI, H-PLL was able to induce partial
mitochondrial depolarization (Fig. 3c).
5. Alternative routes to PLL and PEI mitochondrially
mediated apoptosis
The absence of effect of the Bax channel blocker on the activity of
the L-PLL is intriguing with respect to the route of apoptosis. One
possible explanation could be the induction of genotoxic damage
which can release caspase-2. This protease in its activated form can
directly permeabilize the outer mitochondrial membrane resulting in
release of death promoting proteins in the absence of permeability
transition [54,55]. However, no evidence was obtained for activation
of caspases-2 in this study even after prolonged periods of incubation
with PLL and PLL–DNA complexes. An alternative pathway is the
stimulation of protein kinases and phospholipases by L-PLL [51]. For
example, PLL can induce phospholipase D activation in bovine
pulmonary endothelial cells through the involvement of proteinkinase C [51]. Thus, phospholipase activation via PLL-mediated
plasma membrane damage and involvement of protein kinases may
result in lysolipid transport into the cardiolipin and monolysocardio-
lipin-rich domain of mitochondrion by the lipid transfer capacity of
full-length Bid, altering cardiolipin homoestasis [56]. For instance,
monolysocardiolipin is an inhibitor of mitochondrial phospholipase
A2. Since full-length Bid has an afﬁnity for monolysocardiolipin, this
could result in activation of phospholipase A2 and associated outer
membrane changes such as a positive change in membrane curvature
leading to Cyt-c release.
Limited attention has been focussed on the fate of free cationic
polymers following interaction with other cellular organelles such as
the lysosome following uptake (Fig. 1). The fate of the PEI may be
twofold with known release into the cytoplasm and also end stage
accumulation within the lysosome. Following release of the DNA
payload free PEI would therefore be present in the cytoplasm and
within the lysosome. PEI has been shown to disrupt the lysosomal cell
wall from the cytoplasmic side [57] resulting in potential cathepsin
release. This effect may be repeated on the inner side of the lysosomal
membrane further potentiating cathepsin release. This would elicit a
twofold deleterious effect resulting in generation of executioner
caspases. Firstly, as has been previously observed [58], cathepsins
released from the lysosome into the cytoplasm can cleave the Bcl-2
family member Bid to truncated Bid (tBid) which is recruited to the
mitochondrion (Fig. 1). Interaction of tBid results in oligomerization
of Bax resulting in the formation of a pore in the outer mitochondrial
membrane. This facilitates release of Cyt-c, which then binds to the
apoptotic protease activating factor 1 (Apaf1) as does dATP to form
the oligomeric apoptosome. This complex then binds to and cleaves
pro-caspase-9 to its active form, via a second order process which
occurs on the apoptosome comparable with a dimer driven process
[59]. Caspase-9 then cleaves pro-caspase-3 to caspases-3 triggering
apoptosis. The lysosomal cathepsins released have been shown to
degrade anti-apoptotic Bcl-2 members Bcl-xL or Mcl-2 [58] further
potentiating mitochondrially mediated cell death.
Indeed a similar mechanism has been proposed for the cytotoxic
effect of aminoglycoside antibiotic gentamicin on LLC-PK1 renal cells
[28]. For instance within 2 hours, it relocalize the weak organic base
acridine orange into the cytosol indicating lysosomal membrane
rupture. Loss of MMP occurred after 10 hours (based on JC-1 probe)
with concomitant release of Cyt-c that initiated downstream
executioner caspases. Structurally gentamicin contains−NH2 groups
as do PLL and PEI (Fig. 4), the aforementioned PAMAM dendrimers
and cationic liposomes. These may impart the ability to permeabilize
the lysosome membrane releasing cathepsins, such as cathepsin-D
that may facilitate apoptosis.
A signiﬁcant range of compounds have demonstrated the ability to
induce lysosomal membrane permeabilization (LMP). For example,
the lysosomotrophic detergent MSDH, an imadazoacridineone ana-
logue, when applied at low concentration can partially damage the
lysosome resulting in activation of pro-caspase-3-like proteases and
subsequent apoptosis [60]. This raises an important question about
the ability of macromolecules, which may act as non-ionic and
cationic surfactants under certain cellular conditions [61]. For
example, it is not unreasonable to envisage linear PEI within the
lysosome being oriented into clusters in parts along the length of the
macromolecule. This may impart areas of relatively localized
hydrophilic and hydrophobic portions which together may impart
surfactant activity. Equally sections of the molecule may be shielded
from protonation, through interaction with cellular constituents, with
other sections fully protonated which may impart a “positive head
group”with a hydrophobic chain. In light of this, under certain cellular
conditions it has been suggested that macromolecules can attain
surfactant properties [61], resulting in interaction/disruption of
cellular organelles. This may also offer an alternative mechanistic
explanation for endosomal release of the PEI–DNA complex into the
Fig. 3. The effect of PLL and PLL–DNA complexes on mitochondrial functions. Different PLLs/polyfectin affect Cyt-c release and Bax-channel activity in Jurkat T-cells differently (a).
Western blot analysis (b) comparing Cyt-c release from isolated rat liver mitochondria by different polycations (30 µg/mL) and the effect of H-PLL on rat liver mitochondrial
depolarization. Modiﬁed with permission [26].
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example, it has recently been determined [62] that the total osmotic
pressure exerted by one polyplex particle (∼200 nm), the expected
uptake of a single clathrin-coated vesicle, will result in an expansion
of the membrane area by 2.3%. It has been demonstrated that lipid
vesicles can withstand an area expansion of up to 5% [63].
Silica has been shown to induce lysosomal injury which precedes
apoptosis in mouse alveolar macrophages resulting in an apoptoticFig. 4. Structures of PEI, PLL and gentamicin.pathway involving cathepsin-D and acidic sphingomyelinase [64]. At
the other end of the spectrum, a range of anticancer drugs was able to
induce p53 triggered apoptosis which involved early lysosomal
membrane permeabilization [65]. As such this would indicate that
careful consideration of payload activity as well as, for example,
polyplex behaviour should be determined as dual and potentially
synergistic apoptosis induction may occur in healthy cells. This study
also suggested that LMP is a common mechanism of action of
compounds that induce p53-mediated apoptosis. Furthermore, the
tumor suppressor p53 has recently been shown to utilize the CD95
DISC as an activation platform, where the recruitment of caspase-8 to
this complex is required for caspase-2 activation [66].
Other nanovehicles used for drug delivery applications such as
poly(amidoamine) dendrimers have shown an ability to initiate
mitochondrial-mediated apoptosis where Cyt-c release occurred with
activation of caspase-9 and caspase-3 [67]. Although the dendrimers
were visualized concentrating about the mitochondrion potentially
perturbating the outer membrane, a role for lysosome destabilization
cannot be ruled out. In the case of cationic, liposomes which retain
amino groups also induce apoptosis [68] in a range of cell types.
Investigation of a macrophage-like cell line indicated that a mitogen-
activated kinase (MAPK) that was primarily p38 was initiated by
reactive oxygen species and activated caspases-8 and caspases-8-
dependent cleavage of Bid.
Finally small (b100 nm) PEI–DNA complexes have, following
internalization through caveolae, ended up at the endoplasmic
reticulum [69], and although the effect of interaction at this organelle
has not been deﬁned, it may also result directly in the triggering of
caspase-12, perhaps by induction of stress through interference with
protein folding.
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The central thorn in the side of non-viral gene therapy is
mitochondrially mediated apoptosis by cationic macromolecules.
There is a relative paucity of concentrated studies into the precise
interaction of these polymers within the host cells. Scientiﬁc focus has
primarily been at the events up to release of the vehicle from the
lysosome. Questions regarding the fate of free polymers in the
cytoplasm, their interactionwith other cellular organelles or the activity
of those retained within the lysosome are of pivotal importance, as the
cation organelle interaction may afford other routes to mitochondrially
mediated apoptosis. Understanding of these will enhance our ability to
rationally design new polycation vectors or switch path to new novel
strategies to achieving gene therapy. PEI is not a biodegradable polymer
but investigators have synthesized 144 biodegradable derivatives from
two small PEIs and 24 bi and oligo-acrylate macromolecules [70].
Several of these systems demonstrated low toxicity and high transfec-
tion ability although the toxicity testing used did not determine
apoptosis [71–73]. If a comparatively low molecular weight molecule
containing amino groups such as gentamicin can cause lysosome
destabilization and cathepsin release ultimately triggering the execu-
tioner caspases through the mitochondrion, what is going to be the
effect of concentration of the smaller PEI once degraded within the
lysosome and outside in the cytoplasm? Further, generation of high
polydispersity systems in vivo, as may occur with uneven biodegrada-
tion,may lead to the generation of differentmolecular weight polymers
with speciﬁc bioactivity which may not have beneﬁcial effects [74–76].
Concern has also been raised recently by a study which demonstrated
that nanoparticles can induce DNA damage via signalling from across a
cellular barrier [77]. This further raises questions as to the effects elicited
PEI/PLL–DNA complexes at cellular interface. It is also important to note
the role of mitochondrial membrane potential with associated polyca-
tion accumulation [78]. This may ultimately drive research towards
non-charged or anionic carriers. However, there are examples of
intracellular cationic molecules such as spermine and spermidine, the
levels ofwhichare tightly regulatedbyseveralhomeostaticmechanisms
[26]. Clearly current studies into polycation fate dealt through the hand
of the mitochondrion raise the need for full understanding of cellular
trafﬁcking and fate of macromolecules utilized in gene therapy to
optimise the design of this technology.
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